Market Overview

Goldman Raises Price Target On Accretive Health


Goldman Sachs has published a research report on Accretive Health, Inc. (NYSE: AH) after meeting with company management.

In the report, Goldman Sachs writes "We provide key points from meetings with Accretive Health (AH, Neutral) management and investors: (1) AH emphasized its confidence in the $150mn-$200mn in contracting backlog, stating the majority of contracts are in the very late stages of the process (regulatory clearance). Assuming the contracting backlog closes in the next 30-90 days, PCARRR could near $870 mn in 1Q 2011, which would cover the 2011 revenue consensus of $840 mn without additional backlog conversions. (2) Quality and total cost of care remains an intriguing opportunity, with the current $1 bn Fairview contracts representing only 17% of the total potential Fairview opportunity and our diligence suggests the Fairview contract is likely to expand. Quality EBITDA margins are expected to be negative in the first few quarters and potentially exceed peak RCM margins of 17%-18% by year 3. (3) AH has been able to renegotiate the past 14 RCM contracts at a consistent base fee rate and does not expect base fee erosion in future renegotiations. (4) AH is seeing minimal impact (< 0.5% of revenues) from a weak utilization environment. We are increasing our 2011/2012 EPS to $0.42/$0.68 from $0.41/$0.67 on increased confidence in backlog."

Goldman Sachs maintains its Neutral rating and has raised the price target from $13 to $14.

Accretive Health closed yesterday at $13.99.


Related Articles (AH)

View Comments and Join the Discussion!

Posted-In: accretive health Goldman SachsAnalyst Color Price Target Analyst Ratings

Latest Ratings

MGNXSVB LeerinkMaintains27.0
RCUSSVB LeerinkReiterates42.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at